Related Experiment Videos

Spontaneous regression of breast carcinoma

A N Krutchik, A U Buzdar, G R Blumenschein

Archives of Internal Medicine

|November 1, 1978

Abstract:

Spontaneous regression of breast carcinoma occurred in a patient with a malignant pleural effusion and bone metastases. The patient did not receive any form of hormonal manipulation or systemic chemotherapy. It is postulated that the spontaneous regression of the carcinoma may have been caused by immunological factors.

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials.

Clinical radiology·2020

Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).

Breast cancer research and treatment·2016

Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2015

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

Annals of oncology : official journal of the European Society for Medical Oncology·2015

See all related articles